Tan, Bryan
Pan, Xin-Hui
Chew, Han Shi Jocelyn
Goh, Rachel Sze Jen
Lin, Chaoxing
Anand, Vickram Vijay
Lee, Ethan Cheng Zhe
Chan, Kai En
Kong, Gwyneth
Ong, Christen En Ya
Chung, Hui Charlotte
Young, Dan Yock
Chan, Mark Y. http://orcid.org/0000-0003-0389-7450
Khoo, Chin Meng
Mehta, Anurag
Muthiah, Mark Dhinesh
Noureddin, Mazen
Ng, Cheng Han
Chew, Nicholas W. S. http://orcid.org/0000-0002-0640-0430
Chin, Yip Han http://orcid.org/0000-0002-8417-5996
Article History
Received: 30 December 2022
Revised: 23 April 2023
Accepted: 26 April 2023
First Online: 31 May 2023
Competing interests
: MYC: Speaker’s fees and research grants Astra Zeneca, Abbott Technologies and Boston Scientific. MN: MN has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Siemens and Roche diagnostic; he has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; he is a minor shareholder or has stocks in Anaetos, Rivus Pharma and Viking. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.